| Quantity: | |
|---|---|
Empagliflozin is a Sodium-Glucose Cotransporter 2 Inhibitor. The mechanism of action of empagliflozin is as a Sodium-Glucose Transporter 2 Inhibitor. Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Function
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease. Empagliflozin is also available as a combination product with either metformin and linagliptin as an adjunct to diet and exercise in the management of type 2 diabetes mellitus in adults. An extended-release combination product containing empagliflozin, metformin , and linagliptin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise. Empagliflozin is also approved to reduce the risk of cardiovascular mortality and hospitalization due to heart failure in adult patients with heart failure. In Europe, empagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Empagliflozin is not approved for use in patients with type 1 diabetes.
Package
5.00kg/bag/drum, 5.00kg/bag, 2 bags/drum or according to customer’s requirements.
Empagliflozin is a Sodium-Glucose Cotransporter 2 Inhibitor. The mechanism of action of empagliflozin is as a Sodium-Glucose Transporter 2 Inhibitor. Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Function
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease. Empagliflozin is also available as a combination product with either metformin and linagliptin as an adjunct to diet and exercise in the management of type 2 diabetes mellitus in adults. An extended-release combination product containing empagliflozin, metformin , and linagliptin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with type 2 diabetes mellitus when used adjunctively with diet and exercise. Empagliflozin is also approved to reduce the risk of cardiovascular mortality and hospitalization due to heart failure in adult patients with heart failure. In Europe, empagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. Empagliflozin is not approved for use in patients with type 1 diabetes.
Package
5.00kg/bag/drum, 5.00kg/bag, 2 bags/drum or according to customer’s requirements.
